Study guide

12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

Key Takeaways Explain This Topic AI

Hematopoietic Stem Cell Transplantation (HSCT) is categorized into Autologous (high-dose chemotherapy rescue for chemosensitive relapse or consolidation) and Allogeneic (utilizing donor immune graft to generate a curative Graft-versus-Tumor effect, balanced against Graft-versus-Host Disease).

Busulfan requires mandatory therapeutic drug monitoring (targeting AUC 4800–6000 uM*min for once-daily IV dosing) to prevent catastrophic Hepatic Sinusoidal Obstruction Syndrome (SOS/VOD) at high exposures and graft rejection/relapse at low exposures; levetiracetam is the preferred seizure prophylaxis agent over phenytoin due to lack of CYP3A4 induction.

Hepatic SOS/VOD presents with painful hepatomegaly, jaundice (bilirubin >=2 mg/dL), and rapid ascites/fluid retention (>2–5% weight gain); prophylaxis with ursodiol reduces incidence, while Defibrotide (6.25 mg/kg IV Q6H x >=21 days) is the only FDA-approved treatment, requiring strict withholding of concurrent systemic anticoagulants.

Post-Transplant Cyclophosphamide (PTCy; 50 mg/kg IV on Days +3 and +4 with mesna, plus tacrolimus/MMF from Day +5) has established a new standard for GVHD prophylaxis across haploidentical, matched unrelated, and matched sibling donor transplants (BMT CTN 1703), significantly improving GVHD-free, relapse-free survival (GRFS).

Steroid-refractory acute GVHD (progression after 3 days or non-response after 7 days of IV methylprednisolone 2 mg/kg/day) is treated with Ruxolitinib 5–10 mg PO BID (REACH2 trial, 62% ORR), while steroid-refractory chronic GVHD is managed with Ruxolitinib (REACH3), Belumosudil (ROCK2 inhibitor), Axatilimab (anti-CSF-1R mAb), or Ibrutinib.

Last updated: August 2026

12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

Hematopoietic Stem Cell Transplantation (HSCT) is an intensive, curative-intent therapeutic modality utilized for a broad spectrum of hematologic malignancies and bone marrow failure disorders. Transplants are broadly classified into Autologous HSCT (auto-HCT) , which delivers supralethal chemotherapy to eradicate chemoresistant malignancy followed by autologous stem cell rescue, and Allogeneic HSCT (allo-HCT) , which replaces host hematopoiesis with donor stem cells to exert a persistent, immune-mediated Graft-versus-Tumor (GVT) effect.

Clinical oncology pharmacists practicing in cellular therapy oversee precision busulfan pharmacokinetics, intercept life-threatening drug interactions between calcineurin inhibitors and mold-active triazoles, direct post-transplant cyclophosphamide (PTCy) regimens, and manage complex immunosuppressive regimens for acute and chronic Graft-versus-Host Disease (GVHD).

1. Stem Cell Mobilization & Conditioning Regimens +---------------------------------------------------------------------------------------------------+

  • | STEM CELL TRANSPLANTATION CLASSIFICATION & OBJECTIVES |
  • | |
  • | [AUTOLOGOUS TRANSPLANTATION (Auto-HCT)] |
  • | - Source: Patient's own cryopreserved peripheral blood stem cells (PBSCs) |
  • | - Target Cell Dose: Minimum **>= 2.0 x 10^6 CD34+ cells/kg**; Optimal **>= 5.0 x 10^6 cells/kg** |
  • | - Purpose: Overcome chemoresistance via supralethal chemotherapy (Myeloablation -> Stem Rescue) |
  • | - Key Indications: Relapsed DLBCL/cHL (chemosensitive), Mantle Cell Lymphoma (first remission), |
  • | Multiple Myeloma (upfront consolidation) |
  • | - NO GRAFT-VERSUS-HOST DISEASE (GVHD) RISK; NO GRAFT-VERSUS-TUMOR (GVT) BENEFIT |
  • | |
  • | [ALLOGENEIC TRANSPLANTATION (Allo-HCT)] |
  • | - Source: Donor PBSCs, Bone Marrow, or Umbilical Cord Blood (MSD, MUD, Haploidentical, Mismatch)|
  • | - Purpose: Eradicate host marrow AND establish donor immune system to mediate **GVT Effect** |
  • | - Key Indications: High-Risk AML/ALL, Myelodysplastic Syndromes, Primary Myelofibrosis, |
  • | Relapsed/Refractory Chronic Leukemias and Lymphomas failing targeted therapies |
  • | - BALANCES GRAFT-VERSUS-TUMOR BENEFIT AGAINST GRAFT-VERSUS-HOST DISEASE TOXICITY |
  • +---------------------------------------------------------------------------------------------------+
  • Peripheral Blood Stem Cell (PBSC) Mobilization Strategies

G-CSF Alone (Steady-State): Filgrastim 10 mcg/kg/day SC for 4–5 days; apheresis begins on Day 4 or 5 when peripheral blood CD34+ count is >=10–20/mcL.

Chemomobilization: High-dose chemotherapy (Cyclophosphamide 2–4 g/m2 or disease-specific salvage like ICE/DHAP) followed by G-CSF 5–10 mcg/kg/day starting 24–48 hours post-chemotherapy until completion of apheresis.

Plerixafor (Mozobil) Mobilization: Reversible antagonist of the CXCR4 chemokine receptor , preventing its binding to stromal cell-derived factor-1alpha (SDF-1alpha / CXCL12) on bone marrow stroma, frequency mobilizing CD34+ stem cells into the peripheral circulation within 6–10 hours.

Dosing: 0.24 mg/kg SC administered in the evening (~11 hours prior to apheresis) for up to 4 consecutive days.

Renal Dose Adjustment: If creatinine clearance is <=50 mL/min , reduce dose by one-third to 0.16 mg/kg SC .

Conditioning Regimen Classification +---------------------------------------------------------------------------------------------------+

  • | CONDITIONING INTENSITY SPECTRUM & REGIMENS |
  • | |
  • | [MYELOABLATIVE CONDITIONING (MAC)] |
  • | - Causes irreversible pancytopenia; autologous or allogeneic stem cell support is mandatory |
  • | - **BuCy:** IV Busulfan (AUC targeted) + Cyclophosphamide (120 mg/kg total: 60 mg/kg x 2) |
  • | - **FluBu4:** Fludarabine (160 mg/m2 total) + IV Busulfan (4 days; cumulative AUC ~16,000-20,000|
  • | - **Cy-TBI:** Cyclophosphamide (120 mg/kg) + Total Body Irradiation (12-13.2 Gy in fractions) |
  • | - **BEAM (Auto-HCT):** Carmustine (300 mg/m2 D-6), Etoposide (100-200 mg/m2 BID D-5 to D-2), |
  • | Cytarabine (100-200 mg/m2 BID D-5 to D-2), Melphalan (140 mg/m2 D-1) |
  • | - **Melphalan 200 mg/m2 (Auto-HCT for Myeloma):** Cryotherapy (ice chips) during infusion |
  • | |
  • | [REDUCED-INTENSITY CONDITIONING (RIC)] |
  • | - Causes reversible cytopenias of variable duration; lower regimen-related mortality (RRM) |
  • | - **FluMel:** Fludarabine (120-160 mg/m2) + Melphalan (100-140 mg/m2) |
  • | - **FluBu2:** Fludarabine (120-160 mg/m2) + IV Busulfan (2 days; cumulative AUC ~8,000-10,000) |
  • | - Preferred in older adults (age >=65–70) or patients with significant organ comorbidities |
  • | |
  • | [NON-MYELOABLATIVE (NMA)] |
  • | - Minimal cytopenias; relies entirely on donor immune engraftment to mediate tumor eradication |
  • | - **Flu-TBI (2 Gy):** Fludarabine (90 mg/m2) + low-dose Total Body Irradiation (200 cGy) |
  • +---------------------------------------------------------------------------------------------------+
  • 2. Busulfan Pharmacokinetics, TDM & Seizure Prophylaxis

Busulfan is a bifunctional alkylating agent with a narrow therapeutic window. Intra- and inter-individual pharmacokinetic clearance varies up to 3- to 4-fold due to variations in glutathione S-transferase (GSTA1) activity.

High Exposure (AUC >6,000 uM*min/day or C_ss >1,000–1,500 ng/mL): Strongly correlated with life-threatening Hepatic Sinusoidal Obstruction Syndrome (SOS / VOD) , acute lung injury, and high non-relapse mortality.

Low Exposure (AUC <4,000–4,800 uM*min/day or C_ss <600 ng/mL): Strongly correlated with primary graft rejection/failure and increased disease relapse.

Pharmacist TDM Protocol

Administer test dose or first clinical dose of IV busulfan.

Draw serial blood samples (e.g., at 2h, 4h, 6h post-infusion).

Calculate AUC using non-compartmental or Bayesian pharmacokinetics.

Target: AUC 4,800–6,000 uM min (19.7–24.6 mg h/L) for once-daily IV dosing (Q24H) , or AUC 900–1,350 uM*min for every-6-hour dosing (Q6H) .

Dose Adjust: New Dose = Current Dose × ( Target AUC Actual AUC ) \text{New Dose} = \text{Current Dose} \times \left( \frac{\text{Target AUC}}{\text{Actual AUC}} \right) New Dose = Current Dose × ( Actual AUC Target AUC ​ ) .

Seizure Prophylaxis Mandate

Busulfan crosses the blood-brain barrier rapidly, achieving CSF concentrations equal to plasma, precipitating neurotoxicity and myoclonic/tonic-clonic seizures.

Levetiracetam (Keppra): Preferred first-line agent (500–1,000 mg PO/IV BID). Initiated 6–12 hours prior to the first busulfan dose and continued for 24–48 hours after the final busulfan dose. Does not induce CYP enzymes and does NOT alter busulfan clearance.

Phenytoin (Dilantin): Historically used, but STRONGLY DISCOURAGED because phenytoin is a potent inducer of hepatic CYP3A4 and glutathione S-transferases, significantly increasing busulfan clearance, lowering busulfan AUC, and leading to graft rejection unless intense TDM adjustments are made.

  • 3. Early Transplant Complications & Toxicity Interception
  • Hepatic Sinusoidal Obstruction Syndrome (SOS / Veno-Occlusive Disease [VOD])

Caused by toxic alkylator metabolites injuring sinusoidal endothelial cells and hepatocytes in Zone 3 of the hepatic acinus, leading to microvascular thrombosis, subendothelial fibrin deposition, sinusoidal hypertension, and post-sinusoidal portal hypertension. +---------------------------------------------------------------------------------------------------+

  • | SINUSOIDAL OBSTRUCTION SYNDROME (SOS / VOD) MANAGEMENT |
  • | |
  • | DIAGNOSTIC CRITERIA (Modified Seattle / Baltimore Criteria; typically within Day +21): |
  • | - **Hyperbilirubinemia:** Total Bilirubin >= 2.0 mg/dL |
  • | - **Painful Hepatomegaly:** Right upper quadrant tenderness |
  • | - **Fluid Retention / Ascites:** Rapid, unexplained weight gain (> 2% to 5% from baseline) |
  • | |
  • | PROPHYLAXIS: |
  • | - **Ursodiol (Ursodeoxycholic acid):** 300 mg PO BID to TID (or 12 mg/kg/day) starting prior to |
  • | conditioning and continued through Day +30 (or Day +90 in allo-HCT). Reduces SOS incidence. |
  • | |
  • | DEFINITIVE TREATMENT: |
  • | - **Defibrotide (Defitelio):** Oligonucleotide mixture with profibrinolytic, antithrombotic, |
  • | and endothelial protective properties (enhances tPA, downregulates PAI-1, protects endothelium)|
  • | - **Dosing:** **6.25 mg/kg IV every 6 hours (25 mg/kg/day total)** infused over 2 hours |
  • | - **Duration:** Minimum of 21 days; continue until complete resolution of SOS signs/symptoms |
  • | - **CRITICAL CONTRAINDICATION / SAFETY INTERCEPTION:** |
  • | * Strictly contraindicated in active systemic bleeding or concurrent therapeutic |
  • | anticoagulants (heparin, enoxaparin, DOACs) / systemic thrombolytics (tPA) |
  • | * Discontinue defibrotide >=2 hours prior to invasive procedures; resume after hemostasis |
  • +---------------------------------------------------------------------------------------------------+
  • Engraftment Syndrome

A hyperinflammatory capillary leak syndrome occurring at the time of neutrophil recovery (ANC >=500/mcL for 3 consecutive days), characterized by high fever, diffuse erythematous maculopapular rash, non-cardiogenic pulmonary edema with hypoxemia, weight gain, and renal dysfunction.

Treatment: High-Dose Methylprednisolone 1–2 mg/kg/day IV for 3–5 days with a rapid taper upon symptom resolution.

4. Comprehensive Post-Transplant Infectious Prophylaxis & Drug Interactions +---------------------------------------------------------------------------------------------------+

  • | POST-TRANSPLANT ANTIMICROBIAL PROPHYLAXIS TIMELINE |
  • | |
  • | [PRE-ENGRAFTMENT PHASE (Day 0 to Day +30; Neutropenia ANC <500)] |
  • | - Bacterial: **Levofloxacin 500 mg PO/IV daily** (or Ciprofloxacin) until ANC > 500 |
  • | - Fungal: **Fluconazole 400 mg PO/IV daily** (auto-HCT/low-risk allo) OR **Posaconazole/ |
  • | Voriconazole** (high-risk allo/GVHD) |
  • | - Viral (HSV/VZV): **Acyclovir 400-800 mg PO BID** (or Valacyclovir 500 mg BID) |
  • | - CMV Prophylaxis (Allo-HCT R+): **Letermovir 480 mg PO/IV daily** (Day 0 through Day +100) |
  • | |
  • | [POST-ENGRAFTMENT PHASE (Day +30 to Day +100)] |
  • | - PJP Prophylaxis: **TMP-SMX (Bactrim) 1 DS tablet PO daily or 3x/week** initiated post-engraft-|
  • | ment (ANC >1000, Plt >50k) and continued for >=6 months post-allo and during all GVHD therapy |
  • | - CMV Surveillance: Weekly quantitative CMV PCR in blood |
  • | |
  • | [LATE PHASE (Day +100 to >=1 Year; Chronic GVHD / Immunosuppression)] |
  • | - Continue PJP Prophylaxis (Bactrim DS) + VZV Prophylaxis (Acyclovir) |
  • | - Mold-Active Antifungal (Posaconazole 300 mg DR daily) for active moderate-severe GVHD |
  • | - Encapsulated Bacteria: Penicillin VK 250-500 mg PO BID in patients with active cGVHD |
  • +---------------------------------------------------------------------------------------------------+
  • Critical Pharmacist Drug Interactions & Therapeutic Monitoring

Drug Combination Pharmacokinetic Mechanism Clinical Impact & Pharmacist Interventions

Tacrolimus / Cyclosporine + Voriconazole / Posaconazole Voriconazole and Posaconazole are potent inhibitors of CYP3A4 and P-glycoprotein (P-gp) , blocking the hepatic metabolism of Calcineurin Inhibitors (CNIs). Extreme CNI Toxicity Risk (Nephrotoxicity, Neurotoxicity, HUS/TMA). ; - When adding Voriconazole: Empirically reduce Tacrolimus dose by 66–75% (to 1/3–1/4 of baseline) and Cyclosporine by 50%.; - When adding Posaconazole: Empirically reduce Tacrolimus dose by 66% .; - Check CNI trough levels within 48–72 hours and adjust accordingly. Target Tacrolimus trough: 5–15 ng/mL.

Letermovir + Cyclosporine Cyclosporine inhibits hepatic OATP1B1/1B3 transporters , significantly increasing plasma concentrations of Letermovir. Letermovir Dose Modification Mandate: ; - Standard Letermovir dose: 480 mg PO/IV daily .; - When co-administered with Cyclosporine , reduce Letermovir dose to 240 mg PO/IV daily .; - (Note: Letermovir does not require dose reduction when given with Tacrolimus).

Triazole Antifungal TDM (Voriconazole & Posaconazole) Variable oral bioavailability and non-linear (zero-order) Michaelis-Menten pharmacokinetics (especially voriconazole; CYP2C19 extensive/poor metabolizers). Therapeutic Drug Monitoring (TDM) Mandates: ; - Voriconazole Trough Target: 1.0–5.5 mcg/mL (drawn at steady-state Day 4–7). Levels <1.0 = breakthrough fungal infection; levels >5.5 = visual hallucinations, encephalopathy, severe cholestatic hepatotoxicity, QTc prolongation.; - Posaconazole Target Trough: >0.7 mcg/mL (for prophylaxis); >1.0–1.25 mcg/mL (for treatment of invasive aspergillosis/mucor).

5. Graft-versus-Host Disease (GVHD): Immunobiology, Prophylaxis & Management

GVHD is an immune-mediated disorder wherein immunocompetent donor T-lymphocytes recognize host histocompatibility antigens as foreign, launching a multi-organ cytotoxic attack mediated by alloreactive T-cells and inflammatory cytokines (TNF-alpha, IFN-gamma, IL-1, IL-6, IL-17). +---------------------------------------------------------------------------------------------------+

  • | ACUTE vs. CHRONIC GVHD CLINICOPATHOLOGIC COMPARISON |
  • | |
  • | [ACUTE GVHD (aGVHD)] |
  • | - Onset: Traditionally <=100 days (can occur later as "Late Acute"); rapid, inflammatory |
  • | - Pathophysiology: Donor T-cell activation driven by tissue damage / conditioning cytokines |
  • | - Target Organs: **Skin, Liver, Gastrointestinal Tract (Upper & Lower)** |
  • | - Staging: |
  • | * **Skin:** Stage 1 (<25% BSA maculopapular rash); Stage 2 (25-50% BSA); Stage 3 (>50% BSA / |
  • | generalized erythroderma); Stage 4 (>50% BSA with bullae, desquamation, ulceration) |
  • | * **Liver:** Stage 1 (Bilirubin 2.0-3.0 mg/dL); Stage 2 (3.1-6.0 mg/dL); Stage 3 (6.1-15.0); |
  • | Stage 4 (>15.0 mg/dL) |
  • | * **Lower GI:** Stage 1 (Diarrhea 500-1000 mL/day); Stage 2 (1000-1500 mL/day); Stage 3 |
  • | (>1500 mL/day); Stage 4 (Severe abdominal pain, ileus, or gross bloody stool) |
  • | |
  • | [CHRONIC GVHD (cGVHD)] |
  • | - Onset: Typically >100 days; auto-immune / fibrotic phenotype mediated by Th17/B-cell dysreg. |
  • | - Diagnostic Manifestations: Scleroderma, lichen planus-like skin eruptions, oral ulcerations/ |
  • | mucoceles, keratoconjunctivitis sicca (dry eyes), bronchiolitis obliterans syndrome (BOS: |
  • | drop in FEV1 with air trapping on PFTs), esophageal strictures, joint contractures/fasciitis |
  • +---------------------------------------------------------------------------------------------------+

Modern GVHD Prophylaxis Paradigms +---------------------------------------------------------------------------------------------------+

  • | POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCy) PROPHYLAXIS PROTOCOL |
  • | |
  • | DONOR STEM CELL INFUSION (DAY 0) |
  • | | |
  • | v |
  • | [POST-TRANSPLANT CYCLOPHOSPHAMIDE: Days +3 and +4] |
  • | - **Cyclophosphamide:** **50 mg/kg IV on Day +3 AND Day +4** (with Mesna uroprotection) |
  • | - MOA: Selectively eliminates rapidly proliferating alloreactive donor and host T-cells while |
  • | sparing non-proliferating regulatory T-cells (Tregs) and aldehyde dehydrogenase-high (ALDH+) |
  • | hematopoietic stem/progenitor cells! |
  • | | |
  • | v |
  • | [INITIATION OF DUAL IMMUNOSUPPRESSION: Starting Day +5] |
  • | - **Tacrolimus:** Initiated on Day +5 (Target trough 5-10 ng/mL; tapered starting Day +60-90) |
  • | - **Mycophenolate Mofetil (MMF):** 15 mg/kg PO/IV TID (max 1g TID) starting Day +5 to Day +35 |
  • | - LANDMARK TRIAL: **BMT CTN 1703** (Bolaños-Meade et al. NEJM 2023): PTCy + Tac/MMF |
  • | demonstrated superior 1-year GVHD-Free, Relapse-Free Survival (**GRFS: 52.7% vs. 34.9%**, |
  • | p < 0.001) compared to Tacrolimus + Methotrexate in matched donor reduced-intensity allo-HCT! |
  • +---------------------------------------------------------------------------------------------------+

Systemic GVHD Treatment Algorithms +---------------------------------------------------------------------------------------------------+

  • | FIRST-LINE & STEROID-REFRACTORY GVHD THERAPEUTIC ALGORITHM |
  • | |
  • | NEW-ONSET ACUTE GVHD (Grade II to IV) |
  • | | |
  • | v |
  • | [FIRST-LINE STANDARD: SYSTEMIC HIGH-DOSE CORTICOSTEROIDS] |
  • | - **Methylprednisolone:** **2 mg/kg/day IV** (divided BID or daily; 1 mg/kg/day for Grade II) |
  • | - Response evaluated at Day 7 to 14 (and formal response at Day 28) |
  • | | |
  • | +-------------------------+-------------------------+ |
  • | | | |
  • | v v |
  • | [STEROID-RESPONSIVE] [STEROID-REFRACTORY aGVHD (SR-aGVHD)] |
  • | - Taper steroids slowly over 4 to 8 weeks - Definition: Progression after 3 days of |
  • | - Maintain infection prophylaxis 2 mg/kg, failure to improve by Day 7, |
  • | or incomplete response by Day 14 |
  • | | |
  • | v |
  • | [RUXOLITINIB] (FDA-Approved Category 1) |
  • | - Dose: **5 to 10 mg PO twice daily** |
  • | - **REACH2 Trial:** Superior ORR (62% vs 39%,|
  • | p < 0.001) & longer failure-free survival |
  • | - Monitor: Cytopenias, CMV reactivation |
  • +---------------------------------------------------------------------------------------------------+
  • Targeted Therapeutics for Steroid-Refractory Acute & Chronic GVHD

Drug Name & Class Target & Mechanism Standard Dosing Pivotal Clinical Trial Evidence Essential Pharmacist Monitoring & Toxicities

Ruxolitinib ; (JAK1 / JAK2 Inhibitor) Inhibits Janus kinases 1 and 2, blocking signaling downstream of inflammatory cytokine receptors (IL-6, IFN-gamma, IL-12/23) and suppressing alloreactive T-cell proliferation. Acute GVHD: 5–10 mg PO BID; Chronic GVHD: 10 mg PO BID REACH2 (Acute; Zeiser et al. NEJM 2020): Day 28 ORR 62% vs. 39% (p < 0.001).; REACH3 (Chronic; Zeiser et al. NEJM 2021): ORR 49.7% vs. 25.6% (p < 0.001); superior failure-free survival. Dose-dependent cytopenias (anemia 29%, thrombocytopenia 33%) , lipid elevation, elevated risk of CMV reactivation and opportunistic infections (routine weekly CMV surveillance required). Strong CYP3A4 inhibitors require dose reduction to 5 mg BID.

Belumosudil ; (ROCK2 Inhibitor) Selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) . Rebalances immune homeostasis by downregulating pro-inflammatory Th17 cells while upregulating regulatory T-cells (Tregs), and directly inhibits pro-fibrotic collagen synthesis. 200 mg PO once daily (take with food) KD025-213 Trial (Cutler et al. Blood 2021). Patients with >=2 prior lines of cGVHD therapy: Overall response rate 74–77% , with organ responses across skin, joints, mouth, and lungs. Well tolerated. Common toxicities: AST/ALT elevation, fatigue, nausea, diarrhea, peripheral edema. Co-administration with strong CYP3A inducers requires dose increase to 200 mg PO BID; co-administration with proton pump inhibitors requires dose increase to 200 mg BID.

Axatilimab ; (Anti-CSF-1R Monoclonal Antibody) High-affinity IgG4 mAb targeting the Colony-Stimulating Factor 1 Receptor (CSF-1R) , selectively depleting pathogenic donor-derived monocyte-derived macrophages that drive tissue fibrosis and sclerosis in cGVHD. 0.3 mg/kg IV every 2 weeks AGAVE-201 Trial (Wolff et al. Lancet 2024). Heavily pretreated cGVHD (median 4 prior lines, 74% prior ruxolitinib): ORR 74% at 0.3 mg/kg dose; significant reduction in sclerotic burden. Transient asymptomatic elevation of periorbital edema (14%) , CPK elevation (AST/ALT/CK release from macrophage turnover), fatigue, cough, headache. No severe myelosuppression.

Ibrutinib ; (BTK / ITK Inhibitor) Covalently inhibits Bruton's Tyrosine Kinase (BTK in B-cells) and Interleukin-2-inducible T-cell Kinase (ITK in Th2 cells), inhibiting alloreactive B-cell and T-cell signaling. 420 mg PO once daily PCYC-1129 Trial (Miklos et al. Blood 2017). First FDA-approved drug for steroid-refractory cGVHD (ORR 67%, 71% sustained response >=20 weeks). Bleeding risk, atrial fibrillation, severe diarrhea, fatigue, muscle spasms. Many patients require dose reduction or discontinuation due to adverse effects. Largely superseded by ruxolitinib and belumosudil in modern practice.